Journal: bioRxiv

Article Title: Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells

doi: 10.1101/2022.06.17.496630

Figure Lengend Snippet: Key resource table

Article Snippet: CD86 Antibody, anti-human, PE, REAfinityTM (Clone- REA968) , Miltenyi Biotec , Order Number: 130-116-160.

Techniques: Recombinant, Sterility, Injection, Modification, Staining, Saline, Enzyme-linked Immunosorbent Assay, Multiplex Assay, Software

Journal: Central European Journal of Immunology

Article Title: Macrophage M2 polarization induced by ANKRD22 in lung adenocarcinoma facilitates tumor angiogenesis

doi: 10.5114/ceji.2025.149372

Figure Lengend Snippet: Fig. 2. Cont. F-H) Flow cytometry was used to detect the effects of ANKRD22 overexpression or knockdown on the proportions of CD68+CD86+ and CD68+CD206+ macrophages. All experiments were conducted with 3 independent replicates. The data are presented as mean ± standard deviation. *p < 0.05

Article Snippet: The cells were incubated with PerCP Anti-Human CD68 Antibody (1 : 100; 333813, BioLegend, USA), PE Anti-Human CD86 Antibody (1 : 100; E-AB-F1012D, Elabscience, China), and/or FITC AntiHuman CD206/MMR Antibody (1 : 100; E-AB-F1161C, Elabscience, China) for 15 min. After washing with PBS, the cells were resuspended, and the flow cytometry data were collected and analyzed using Agilent’s flow analysis software.

Techniques: Flow Cytometry, Over Expression, Knockdown, Standard Deviation

Journal: Central European Journal of Immunology

Article Title: Macrophage M2 polarization induced by ANKRD22 in lung adenocarcinoma facilitates tumor angiogenesis

doi: 10.5114/ceji.2025.149372

Figure Lengend Snippet: Fig. 2. Cont. I) Flow cytometry was used to detect the ef- fects of ANKRD22 overexpression or knockdown on the pro- portions of CD68+CD86+ and CD68+CD206+ macrophages. J) WB was used to detect the effects of ANKRD22 over- expression or knockdown on the protein expression levels of CD80 and CD163. All experiments were conducted with 3 independent replicates. The data are presented as mean ± standard deviation. *p < 0.05

Article Snippet: The cells were incubated with PerCP Anti-Human CD68 Antibody (1 : 100; 333813, BioLegend, USA), PE Anti-Human CD86 Antibody (1 : 100; E-AB-F1012D, Elabscience, China), and/or FITC AntiHuman CD206/MMR Antibody (1 : 100; E-AB-F1161C, Elabscience, China) for 15 min. After washing with PBS, the cells were resuspended, and the flow cytometry data were collected and analyzed using Agilent’s flow analysis software.

Techniques: Flow Cytometry, Over Expression, Knockdown, Expressing, Standard Deviation

Journal: Science Advances

Article Title: Biofunctional lipid nanoparticles for precision treatment and prophylaxis of bacterial infections

doi: 10.1126/sciadv.adk9754

Figure Lengend Snippet: ( A ) Expression levels of CD80 + and CD86 + in BMDCs (CD11c + ) and ( B ) production of IL-6 and TNF-α of the cell supernatant measured by ELISA after different treatments (concentration, 2 μg ml −1 NPs) for 24 hours ( n = 3). ( C ) Schematics of experimental design to evaluate the in vivo short-term immune responses activated by a single dose of various LNPs (20 μg/20 g) via subcutaneous injection. ( D ) Percentage of CD80 + and ( E ) CD86 + cells (gated on CD11c + cells) in the LNs at day 3 after immunization ( n = 6). ( F ) Percentage of CD3 + T cells, ( G ) CD8 + T cells (gated on CD3 + T cells), and ( H ) CD4 + T cells (gated on CD3 + T cells) in the spleen at day 3 after immunization ( n = 6). Naive mice without immunization were used as control. * P < 0.05, ** P < 0.01, and *** P < 0.001.

Article Snippet: Fluorescein isothiocyanate (FITC)–conjugated anti-mouse CD11c, phycoerythrin (PE)–conjugated anti-mouse CD80, PE-conjugated anti-mouse CD86, allophycocyanin (APC)–conjugated anti-mouse CD3, PE-conjugated anti-mouse CD8a, and FITC-conjugated anti-mouse CD4 were purchased from Tonbo Biosciences, USA.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, In Vivo, Injection, Control

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation.

doi: 10.4049/jimmunol.171.5.2384

Figure Lengend Snippet: FIGURE 9. CT enhances CD80 and CD86, but inhibits CD40 and ICAM-1 expression on DC. DC were stimulated with medium alone, CT (1 g/ml), LPS (10 ng/ml), or CT plus LPS in the presence or the absence of anti-IL-10 (10 g/ml). After 24-h incubation, cells were washed and stained with Abs specific for CD80, CD86, OX40, CCR5, ICAM-1, and CD40 or with isotype-matched control Abs. Immunofluorescence is shown for treated (black line) compared with untreated (gray histograms) DC. The numbers on the right of each histogram refer to the mean fluorescence intensity of the treated cells; the value for cells treated with medium alone is presented on the left of the first histogram in each case. Profiles are shown for a single experiment and are representative of five experiments.

Article Snippet: The expression of DC surface markers was assessed using anti-mouse CD40 (rat IgG2a, clone 3/23), I-A d (mouse IgG2b, clone AMS-32.1), CD80 (hamster IgG2, clone 16-10A1), CD86 (rat IgG2a, clone GL1), CD11c (hamster IgG1, clone HL3), and CD134 (OX40; rat IgG1, clone OX86; Serotec, Oxford, U.K.).

Techniques: Expressing, Incubation, Staining, Control

Journal: Frontiers in Immunology

Article Title: Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance

doi: 10.3389/fimmu.2023.1161869

Figure Lengend Snippet: Anti-PD-1/CTLA-4/Ly6C treatment reduces tumor growth and increases CD8 T cells/dendritic cells. (A) 344SQ tumor bearing 129/Sv mice were weekly treated with anti-PD-1_CTLA-4 (200 µg of anti-PD-1 plus 200 µg of anti-CTLA-4 per mouse), anti-Ly6C alone (200 µg of anti-Ly6C per mouse), anti-PD-1_CTLA-4_Ly6C (200 µg of anti-PD-1 plus 200 µg of anti-CTLA-4 plus 200 µg of anti-Ly6C per mouse), or their IgG control mixture (IgG control) beginning on week 2 after a subcutaneous cancer cell injection (1 x 10 6 cells per mouse; n = 5) for 4 weeks. Mice received total of 4 treatments starting at week 2 post tumor cell implantation. (B) tSNE CD45 plots from 344SQ tumors treated with IgG control, anti-PD-1_CTLA-4, or anti-PD-1_CTLA-4_Ly6C from (A) . Tumors from (A) were harvested to prepare single cell suspensions for FACS analysis. (C) Percentages of CD8 T cells (left), Effector/memory CD8 T cells (middle), and dendritic cells (right). (D) Percentage of Ly6C- (left) and Ly6C+ (right) CD14+CD115+ monocytes. Kras LSL-G12D /p53 fl/fl mice generated through intratracheal administration of adenovirus expressing Cre recombinase were treated with either anti-PD-1/CTLA-4 or anti-PD-1/CTLA-4/Ly6C for 8 weeks (E) Micro-CT images shown at week 0 (baseline) and week 8 (endpoint) for anti-PD-1/CTLA-4 or anti-PD-1/CTLA-4/Ly6C. Dashed yellow circles indicate lung tumors. H indicates of heart. (F) Percentage change of tumor area was calculated taking into account prior time point and normalized to the baseline measurement. (G) H&E stained lung sections at week 8 from anti-PD-1/CTLA-4 or anti-PD-1/CTLA-4/Ly6C treated mice from (E) . bar= 5 mm. (H) Number of lung tumors on H&E sections from (G) treated with anti-PD-1/CTLA-4 or anti-PD-1/CTLA-4/Ly6C weekly for 8 weeks. (I) IHC of CD8 stained lung tumors from (F) week 8. Percentage of CD8 T cells found in the lung tumors from Kras LSL-G12D /p53 fl/fl mice treated for 8 weeks with anti-PD-1/CTLA-4 or anti-PD-1/CTLA-4/Ly6C. (J) The dendritic cells from CD11c-DTR mice were transferred into C57BL/6 mice to generate the chimerical mice, after 8-week stabilization, the mice were treated with diphtheria toxin twice a week to maintain the depletion of dendritic cells. The B16 melanoma-bearing mice were treated weekly with anti-PD-1_CTLA-4_Ly6C for 3 weeks staring on week 1 after tumor cells inoculation. (K) 344SQ tumor bearing 129/Sv mice were treated weekly with blockade of PD-1, CTLA-4, and Ly6C (200 µg of anti-PD-1 plus 200 µg of anti-CTLA-4 plus 200 µg of anti-Ly6C per mouse) or their IgG control mixture (IgG control) beginning on day 7 after a subcutaneous cancer cell injection (0.1 x 10 6 cells per mouse; n = 5) for 4 weeks. For blocking B7 signal, antibodies (anti-B7: 300 μg of anti-CD80 and 300 μg of anti-CD86 per mouse) were intraperitoneally administered 1 day before the first dose of therapy, and then once a week to maintain the blockade. ANOVA test was used to analyze the data. n.s., not significance; *p < 0.05; **p < 0.01; ***p< 0.001; ****p < 0.0001.

Article Snippet: Anti-mouse PD-1 (clone RMP1-14), anti-mouse CTLA-4 (clone 9D9), anti-mouse CD80 (clone 16-10A1), anti-mouse CD86 (clone GL-1), anti-mouse Ly6C (clone Monts 1), anti-mouse CCL2 (clone 2H5), and the isotype-matched IgG controls were purchased from BioXCell.

Techniques: Control, Injection, Generated, Expressing, Micro-CT, Staining, Blocking Assay